公司已上市创新药数量达十款，创新药收入27.76亿元，同比增长26%，占总收入比例首次超过3/4，达 77.4%。2025年上半年2款创新药获批上市、2款候选药物进入NDA审评阶段，另有2款自研临床阶段产 品实现创新出海授权，创新转型成果亮眼。 三大领域10款创新产品协同发力 在公司聚焦的三大业务板块：神经科学营收12.49亿元、抗肿瘤营收8.74亿元、自免疾病领域营收8.78亿 元，相关产品分别贡献了集团收入的34.8%、24.4%、24.5%，较2024年同期增长37.3%、41.1%、3.3%。 8月21日，先声药业（02096.HK）发布2025年中期业绩报告。2025年上半年，先声药业集团总营业收入 同比增长15.1%至35.85亿元，经调整净利润6.51亿元，同比增长21.1%。 "三个5"创新产品梯队成型，推动先声迈入加速发展新阶段。 除却国内市场，随着SIM0500三抗美国I期临床患者用药、Polθ抑制剂SIM0508等多款在研新药中美临床 双报成功，先声正在加速全球化布局。 2025年上半年，先声药业旗下抗肿瘤创新药子公司先声再明与艾伯维（AbbVie）、NextCure分别就自研 GPRC ...

Core Insights - Taiping Medical Health Fund has completed an investment in Hainan Xiansheng Zaiming Pharmaceutical Co., Ltd., a subsidiary of Xiansheng Pharmaceutical Group, which is a leading domestic pharmaceutical company focused on innovative anti-tumor drugs [1] - The investment aims to enhance Xiansheng Zaiming's innovative capabilities and support its participation in international competition and collaboration in tumor immunotherapy [1] - Xiansheng Zaiming has developed several advanced research and development platforms, including protein engineering, T cell engagers, NK cell engagers, ADCs, PROTACs, and AI-assisted molecular design [1] Company Developments - Xiansheng Zaiming has achieved compliance with GMP standards in both China and the United States for its independent production capabilities [1] - The company has four core innovative drugs, namely Kexaila®, Envida®, Endu®, and Enlitai®, which are already commercialized and cover various solid tumor treatments [1] - Kexaila® and Enlitai® are expected to enter the national medical insurance catalog in 2024, following Endu® [1] Strategic Partnerships - Following the investment, Xiansheng Zaiming announced a strategic partnership with Next Cure, Inc. to co-develop a new ADC drug, SIM0505, targeting the CDH6 antigen for solid tumor treatment [3] - The potential development phase of SIM0505 could yield up to $745 million in related payments, including upfront, development, and sales milestone payments, along with tiered royalties based on net sales outside Greater China [3] - Previously, Xiansheng Zaiming entered a licensing option agreement with AbbVie for SIM0500, a tri-specific antibody, with a total value of up to $1.055 billion [6]